Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
PICKRCC trial: what clinicians have said so far
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
- NCT03905889 ↗
- Terminated
- Brown University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on PICKRCC (abemaciclib plus sunitinib in metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PICKRCC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib Study of Abemaciclib (VerzenioTM) in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Renal Cell Carcinoma Metastatic
- Interventions
- Abemaciclib; Sunitinib
- Arms
- Experimental Abemaciclib and Sunitinib · Experimental
- Enrollment
- 3
- Primary outcomes
- Maximum tolerated dose (MTD)
- Continued Toxicity assessment of the maximum tolerated dose (i.e the recommended Phase II dose) of Abemaciclib and Sunitinib as determined from the from dose escalation phase.
- Pharmacokinetic Assessment of Abemaciclib and Sunitinib trough levels at steady state
- Sponsor
- Brown University with Eli Lilly and Company
- Start
- Jun 5, 2019
- Primary completion
- Mar 8, 2022
- Results posted
- No
- Registry record
- NCT03905889 · updated Jun 25, 2024